The stock price of Biomea Fusion Inc has fallen significantly despite the release of positive clinical trial data. This could be due to a variety of factors not mentioned in the article, such as market conditions, investor expectations, or profit-taking. However, based on the information provided, the positive results would typically be expected to have a positive impact on the stock price, suggesting that the drop may be short-lived or related to external factors.